Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.36 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.36 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074827 | 0.92 | CHEK1 (0.40) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL1074802 | 0.90 | MTOR (0.44) | MTORRPTORMLST8SYKCYP4F2 | |
| SCHEMBL10328265 | 0.89 | MTOR (0.35) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL6891563 | 0.82 | MTOR (0.42) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL6891576 | 0.81 | CHEK1 (0.39) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL1076518 | 0.79 | MTOR (0.43) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL10277447 | 0.77 | MTOR (0.52) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL6892350 | 0.77 | MTOR (0.52) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL6891270 | 0.77 | MTOR (0.38) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL1073807 | 0.76 | MTOR (0.41) | MTORRPTORMLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 14/4885 |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | MTOR 1824/4885RPTOR 3265/4885MLST8 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.